Jenburkt Pharmaceuticals Ltd

Jenburkt Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jenburkt Pharmaceuticals Ltd

₹ 702 1.01%
29 Sep 4:01 p.m.
jenburkt.com BSE: 524731
About

Incorporated in 1985, Jenburkt Pharmaceuticals Limited is engaged in the manufacturing, producing, developing and marketing of a wide range of branded pharmaceutical formulations and healthcare products.

Key Points

Brands
The company houses 85 brands, prominent ones being:
Allerzine, Cartisafe, Eberjen, Ecoprot, Lutriben, Metmin-A, Nervijen, Numox, Ojen, Piritexyl, Powergesic, Rabera, Topcal, Triben, Zix, Zydol, etc. [1]

Website BSE
  • Market Cap ₹ 322 Cr.
  • Current Price ₹ 702
  • High / Low ₹ 800 / 531
  • Stock P/E 13.4
  • Book Value ₹ 267
  • Dividend Yield 2.05 %
  • ROCE 26.6 %
  • ROE 20.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 26.3%

Cons

  • The company has delivered a poor sales growth of 3.58% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
17.43 30.48 31.82 29.56 27.18 35.51 33.00 28.29 31.13 35.85 34.57 35.20 29.18
16.81 23.31 24.80 24.53 21.82 25.24 26.03 23.64 23.85 27.24 27.59 27.71 22.22
Operating Profit 0.62 7.17 7.02 5.03 5.36 10.27 6.97 4.65 7.28 8.61 6.98 7.49 6.96
OPM % 3.56% 23.52% 22.06% 17.02% 19.72% 28.92% 21.12% 16.44% 23.39% 24.02% 20.19% 21.28% 23.85%
0.98 1.02 1.05 1.26 1.19 1.19 1.29 1.28 1.14 1.26 1.46 1.26 1.04
Interest 0.11 0.12 0.12 0.12 0.10 0.11 0.10 0.12 0.09 0.09 0.10 0.08 0.07
Depreciation 0.49 0.51 0.51 0.53 0.43 0.45 0.47 0.54 0.54 0.54 0.58 0.59 0.50
Profit before tax 1.00 7.56 7.44 5.64 6.02 10.90 7.69 5.27 7.79 9.24 7.76 8.08 7.43
Tax % -1.00% 25.00% 20.16% 31.38% 22.76% 26.88% 18.99% 34.54% 23.62% 25.65% 29.90% 21.29% 27.73%
1.01 5.67 5.95 3.88 4.65 7.97 6.23 3.45 5.95 6.87 5.43 6.35 5.37
EPS in Rs 2.20 12.35 12.96 8.45 10.13 17.37 13.57 7.52 12.96 14.97 11.83 13.84 11.70
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
60 69 76 85 94 103 115 123 119 109 124 137 135
50 59 65 70 77 84 91 98 99 89 97 106 105
Operating Profit 9 10 12 15 16 20 24 25 20 20 27 30 30
OPM % 16% 15% 15% 18% 18% 19% 21% 20% 17% 18% 22% 22% 22%
1 1 2 2 3 3 3 3 4 4 5 5 5
Interest 1 1 1 0 0 0 0 0 1 0 0 0 0
Depreciation 1 1 2 3 2 2 2 1 2 2 2 2 2
Profit before tax 9 9 10 14 17 20 25 27 21 22 30 33 33
Tax % 30% 30% 27% 33% 36% 34% 32% 26% 30% 24% 25% 25%
6 6 8 10 11 14 17 20 15 16 22 25 24
EPS in Rs 12.91 13.38 16.15 20.76 23.19 29.06 37.50 43.14 32.40 35.95 48.59 53.62 52.34
Dividend Payout % 27% 31% 32% 30% 31% 28% 24% 24% 25% 28% 25% 26%
Compounded Sales Growth
10 Years: 7%
5 Years: 4%
3 Years: 5%
TTM: 5%
Compounded Profit Growth
10 Years: 15%
5 Years: 7%
3 Years: 18%
TTM: 2%
Stock Price CAGR
10 Years: 27%
5 Years: -1%
3 Years: 22%
1 Year: 30%
Return on Equity
10 Years: 24%
5 Years: 21%
3 Years: 20%
Last Year: 21%

Balance Sheet

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
5 5 5 5 5 5 5 5 5 5 5 4
Reserves 14 18 23 29 36 50 57 73 75 94 113 118
2 5 2 7 5 6 0 7 3 5 7 3
19 22 15 21 12 16 16 18 21 17 18 16
Total Liabilities 40 49 44 61 58 76 77 103 104 120 143 141
13 14 14 12 12 11 10 10 12 11 11 10
CWIP 0 0 0 0 0 0 0 1 0 0 0 1
Investments 1 0 0 0 1 2 5 5 4 7 8 11
26 34 30 49 45 64 62 87 88 103 123 119
Total Assets 40 49 44 61 58 76 77 103 104 120 143 141

Cash Flows

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
7 5 11 9 8 10 16 13 15 19 9 17
-3 -1 0 1 -0 -10 1 -11 -3 -19 -1 3
-2 0 -7 1 -5 1 -18 -2 -11 -1 -6 -21
Net Cash Flow 2 3 5 11 2 1 -1 0 1 -0 3 -1

Ratios

Figures in Rs. Crores

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 22 32 26 32 23 32 40 68 55 47 45 45
Inventory Days 116 123 93 107 109 128 73 99 120 92 115 92
Days Payable 42 49 59 54 44 72 44 66 58 56 83 67
Cash Conversion Cycle 97 106 61 85 88 89 69 101 117 83 77 70
Working Capital Days 44 53 10 18 26 32 25 57 43 31 35 39
ROCE % 48% 40% 41% 42% 40% 39% 42% 37% 26% 24% 26% 27%

Shareholding Pattern

Numbers in percentages

1 Recently
Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023
45.73% 45.73% 45.73% 45.73% 45.73% 45.73% 45.73% 45.73% 45.74% 45.96% 47.56% 47.56%
2.22% 2.22% 2.57% 4.37% 4.37% 4.37% 4.37% 4.37% 4.79% 3.49% 2.70% 1.79%
52.05% 52.05% 51.70% 49.90% 49.90% 49.90% 49.90% 49.90% 49.48% 50.52% 49.73% 50.65%
No. of Shareholders 7,0306,9566,8256,8736,6266,1166,0536,0165,8965,7845,6115,741

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings